Sodium fusidate topical spray - Lipidor
Alternative Names: AKP-03Latest Information Update: 28 Jan 2025
At a glance
- Originator Lipidor
- Class Antibacterials; Skin disorder therapies
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Eczema; Impetigo
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for preclinical development in Eczema in Sweden (Topical, Spray)
- 12 Jan 2023 Sodium fusidate is still in preclinical development for Eczema in Sweden (Topical, Spray) (Lipidor pipeline, January 2023)
- 28 Dec 2022 No recent reports of development identified for preclinical development in Eczema in Sweden (Topical, Spray)